Anti-Certolizumab Polyclonal Antibody (AF879054)

Name: Anti-Certolizumab Polyclonal Antibody
Brand: abinScience
SKU: AF879054
Price: 168 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

50ug
100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

AF879054

Descripción

Anti-Certolizumab Polyclonal Antibody (AF879054) is a rabbit polyclonal antibody detecting Certolizumab in ELISA.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.

Reactividad de especies

General

Aplicaciones

ELISA

Especie huésped

Rabbit

Clonalidad

Polyclonal

Isotipo

IgG

Inmunógeno

Certolizumab

Objetivo

Certolizumab

Especificidad

The product is specific for Certolizumab. This antibody serves as an excellent positive control for Certolizumab immunogenicity (ADA) assays.

Nivel de endotoxinas

Please contact with the lab for this information.

Pureza

>90% as determined by SDS-PAGE.

Purificación

Purified by antigen affinity column.

Número de acceso

CAS: 428863-50-7

Forma

Liquid

Buffer de almacenamiento

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:5000-1:20000
IHC	1:50-1:500
WB	1:500-1:2000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

Certolizumab is a Fab fragment of a monoclonal antibody to human tumor necrosis factor alpha (TNFα) which has potent antiinflammatory activity and is used in the therapy of severe rheumatoid arthritis and inflammatory bowel disease. Antibodysystem Anti-Certolizumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Certolizumab.
• Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial., PMID:37423647
• Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis., PMID:32207094
• Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy., PMID:33769772
• Certolizumab treatment of localized pyoderma gangrenosum in a pregnant patient., PMID:37905433
• Certolizumab pegol for hidradenitis suppurativa: Case report and literature review., PMID:33135826
• Certolizumab pegol for induction of remission in Crohn's disease., PMID:31476018
• ACG Clinical Guideline: Management of Crohn's Disease in Adults., PMID:29610508
• [Certolizumab]., PMID:31208736
• Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation., PMID:27140438
• Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis., PMID:31917928

Nota

For research use only.

Imágenes

Referencias

Datasheet